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Summary There is variation in the treatment of lower limb cellulitis (LLC) with no agreement
on the most effective antibiotic regimen. Many patients with cellulitis fail to respond
to first-line antibiotics. This can negatively affect patient care and result in unneces-
sary hospital admissions. The aim of this systematic review was to determine the clin-
ical response and safety of antibiotic regimens for the management of LLC. A
systematic review for randomized controlled trials (RCTs) was conducted using OVID
MEDLINE, Ovid Embase and Cochrane Central Register of Controlled Trials in January
2019. Outcomes of interest included the clinical response to antibiotic regimens (type,
dose, route, duration) and the safety of antibiotics in LLC. Trial quality was identified
using the Cochrane Risk of Bias tool. Four RCTs were included. All included studies
showed no significant differences between the clinical response to different antibiotic
type, administration route, treatment duration or dose. LLC may be overtreated and
shorter courses of oral antibiotics, possibly with lower doses, may be more suitable.
There is a lack of published data on the clinical response and safety of antibiotics in
LLC. Three studies were high risk for bias overall. Further high-quality studies may
help determine whether less intensive antibiotic regimens can effectively treat LLC.
Introduction
During 2017, 88 664 National Health Service (NHS)
patients were admitted to hospitals in the UK with cel-
lulitis, receiving inpatient treatment costing £226m.1,2
Without effective treatment, cellulitis may cause sepsis
and recurrent disease.3 Given the prevalence and con-
sequences of cellulitis, it is essential to effectively man-
age this condition.
The antibiotic choice to treat cellulitis is influenced
by hospital guidelines, causative bacteria and clinical
experience.4,5 One review identified 25 different
antibiotic regimens across 5 emergency departments.6
A study of over 100 hospitals showed that 16.6%
of patients with acute cellulitis experienced initial
antibiotic failure.7
A previous review highlighted a lack of high-qual-
ity studies and was unable to define best treatment
for cellulitis.4 However, it was conducted 9 years
ago and did not focus on the lower limb, which is
affected by cellulitis in 66% of cases.8 Lower limb
cellulitis (LLC) may behave differently from cellulitis
at other sites, owing to differences in circulation and
flora.
The 2017 Cellulitis Priority Setting Partnership
(PSP), emphasized concern from patients and clini-
cians for more conclusive treatment guidelines.9 This
review aimed to better define how best to treat LLC.
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Methods
Reporting
This review was reported in line with the Preferred
Reporting Items for Systematic Reviews and
Meta-analyses (PRISMA) statement. The protocol was
registered with PROSPERO in January 2019
(CRD42019116416).
Outcome
The primary outcome was the clinical response to the
antibiotic regimen (type, dose, route, duration). Clini-
cal response was operationalized using validated out-
come measures,10,11 namely, symptom response,
laboratory markers, therapeutic failure and quality of
life. One of the authors (PS) is a patient expert, and
ensured the review was patient-focused. The secondary
outcome was the frequency of adverse events.
Study types
Studies included randomized conrolled trials (RCTs) of
patients with LLC, in which the clinical response to
antibiotics was evaluated. No restrictions on study
date or patient demographics were applied. The exclu-
sion criteria included: manuscript not in English; use
of prophylactic antibiotics; and presence of eosinophilic
cellulitis. Full eligibility and exclusion criteria are
given in Table S1 online.
Search strategy
The search (Table S2) was developed with an informa-
tion specialist (DG) and cellulitis expert (NJL). Ovid
MEDLINE, Ovid Embase and the Cochrane Central
Register were searched on 5 January 2019 using key
terms (Table 1). Grey literature was identified using
National Institute for Health and Care Excellence evi-
dence and Google Scholar. The World Health Organi-
zation (WHO) International Clinical Trials Registry
Platform was screened for unpublished studies. De-
duplication was performed using EndNote X9 (https://
endnote.com). The reference lists of included studies
were scanned for eligible studies.
Analysis
Eligibility screening, data extraction and quality
assessment was performed independently by KM and
SS. Disagreements were resolved through a third
reviewer (NJL). Data was entered into Revman 5.3
(Cochrane Library). Studies were described in narrative
synthesis. Methodological quality was assessed using a
modified version of the Cochrane risk of bias (RoB)
tool.12 For each domain a study was assessed as ‘low
risk’ if all signalling questions were ‘yes’, ‘high risk’ if
at least one signalling question was ‘no’ or ‘unclear’ if
not reported. If a study was ‘high risk’ in any domain,
it was considered ‘high risk of bias’ overall. If a study
was ‘unclear risk’ in multiple domains, it was consid-
ered to have ‘some concerns of bias’ overall.12
Results
The PRISMA diagram shows the search result (Fig. 1).
Only four studies were eligible (Table 2).13–16 In total,
529 patients were included across 13 countries. Two
studies were based in hospitals.13,15 No studies
reported who had made the diagnosis or the duration
of LLC. Two studies defined LLC diagnosis.15,16 Two
studies specified LLC severity and excluded patients
with mild disease.14,16 No studies compared the same
antibiotic regimen, hence I2 and meta-analysis was
inappropriate.
Leman and Mukherjee showed that the addition of
intravenous (IV) benzylpenicillin to IV flucloxacillin
did not result in a more rapid clinical response
(Tables 3 and 4).13
Peterson et al. demonstrated that 2 of 8 patients
(25%) on ciprofloxacin 1500 mg and 6 of 8 (75%) on
2000 mg achieved a long-term satisfactory response
[relative risk (RR) = 0.33, 95% CI 0.09–1.18].16 This
raises the possibility that in some patients lower doses
of ciprofloxacin could potentially be used with no
reduction in clinical response.16
Joseph et al.14 performed a pooled analysis of the
ESTABLISH 1 and 2 trials.17,18 In the tedizolid group
114 of 162 patients (70.4%) achieved early clinical
response compared with 115 of 158 (72.8%) in the
Table 1 PICOS framework for search strategy.
Parameter Key terms
Population Patients with lower limb cellulitis or lower limb
erysipelas
Intervention Antibiotics
Comparison Another treatment for cellulitis, placebo,
nothing
Outcome Improved clinical outcomes such as symptom
response, changes in laboratory markers,
therapeutic failure or quality of life
Study design Randomized controlled trial
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linezolid group (RR = 0.97, 95% CI 0.84–1.1).14 At
post-therapy evaluation 139 of 162 (85.8%) in the
tedizolid group and 136 of 158 (86.1%) in the line-
zolid group showed a clinical response (RR = 1.00,
95% CI 0.91–1.09), confirming noninferiority of tedi-
zolid.14 Tedizolid offered a short and well-tolerated
treatment.14
Zeglaoui et al. revealed that 11 of 55 patients (20%)
on IV benzylpenicillin and 8 of 57 (14%) on intramus-
cular (IM) bipenicillin had failure of treatment at Day
10 based on their symptoms (RR = 1.43, 95% CI
0.62–3.27).15 Mean time to recovery was 6.3 days in
patients on IV benzylpenicillin compared with
6.5 days in patients on IM bipenicillin (t-test,
P = 0.75).15 This suggested that IM bipenicillin could
be a possible alternative to IV benzylpenicillin.15
Zeglaoui et al. also found that 9.1% (4/44) on IV
benzylpenicillin and 7% (3/44) on IM bipenicillin
experienced local skin complications such as cuta-
neous necrosis (RR = 1.33, 95% CI 0.32–5.61).15 The
authors reported that 14/44 (25.5%) patients on IV
benzylpenicillin experienced venitis, whereas no
patients on IM bipenicillin did (RR = 29.00, 95% CI
1.78–471.58).15 By contrast, Leman and Mukherjee
identified no adverse effects for benzylpenicillin.13
RoB was high for three of these studies,13,15,16 and
there were some concerns about RoB in the fourth14
(Fig. 2). One study did not provide the baseline
characteristics.16 Leman and Mukherjee reported that
18 of 99 participants (18%) withdrew from the study,
and identified deviation from standard practice due to
the early discharge of participants.13 The study of Peter-
son et al. was underpowered to show a significant differ-
ence.16 Two studies used subjective outcome
measures.15,16
Discussion
All included studies showed no significant differences
between groups related to antibiotic types, administra-
tion routes (IV and alternative routes), durations of
treatment (long vs. short) or dosages (high vs. low).
This suggested that LLC may be overtreated in some
patients. Another review, which included sites other
than the lower limb also showed oral route, lower
dosages and shorter durations of antibiotics to be
equally effective.19
The first surveillance data by the WHO on antimi-
crobial resistance, published in 2018, revealed that
penicillin resistance ranged from 0 to 51% globally.20
The first-line antibiotic in the UK is flucloxacillin,5 but
this is ineffective against methicillin-resistant Staphylo-
coccus aureus (MRSA) and its broad-spectrum action
potentiates resistance.21,22 Flucloxacillin can also be
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Table 2 Characteristics of the four included studies.
Reference
Leman and Mukherjee,
200513 Joseph et al., 201714 Zeglaoui et al., 200415 Peterson et al., 198916
Country, setting Single tertiary emergency
department at an
inner-city teaching
hospital in the UK
ESTABLISH 1 – North
America, South America,
Europe
Department of Dermatology,
Charles Nicolle Hospital,
Tunisia
Minneapolis Veterans
Administration Medical
Center, MN, USA
ESTABLISH 2 – South
America, Oceania, Europe,
New Africa, North America
Years of study 2001–2003 ESTABLISH 1: 2010–2011 1994–1999 Unclear
ESTABLISH 2:2011–2013
Study type Double-blind,
randomized, placebo-
controlled trial
ESTABLISH 1 and 2:
randomized, double-blind,
phase III trials
Prospective, randomized,
monocentric trial
Double-blind, randomized
controlled trial
Diagnoses
explored in the
study
LLC Cellulitis, erysipelas, major
cutaneous abscess, wound
infection
Erysipelas of leg Cellulitis or osteomyelitis with
comorbid peripheral
vascular disease
Funding source Unclear ESTABLISH 1: Trius
Therapeutics
Unclear Miles Pharmaceuticals
ESTABLISH 2: Cubist
Pharmaceuticals
Patients with LLC
analysed, n
81–41 (I); 40 (C) 320–162 (I); 158 (C) 112–57 (I); 55 (C) 16–8; 8 (C)
Mean age of
patients with
LLC, years
44.9 (I); 46.4 (C) 47.6* (I); 47.9* (C) 44 (I); 41.4 (C) 64a
Male patients
with LLC, n (%)
35 (85%) (I); 30 (75%)
(C)
158 (58.5%) (I)a; 159
(56.4%) (C)a
29 (50.9%) (I); 28 (51%) (C) 47* (98%)a
Intervention IV flucloxacillin 1 g four
times daily plus IVa
benzylpenicillin 1.2 g
once daily
Oral tedizolid 200 mg once
daily for 6 days
IM bipenicillin
(benzylpenicillin + procaine
penicillin) 2 MU twice daily
for 10 days
Oral ciprofloxacin 1000 mg
twice daily 3 weeks
Control IV flucloxacillin 1 g four
times daily plus normal
saline placebo
Oral linezolid 600 mg twice
daily for 10 days
IV benzylpenicillin 4 MU 4 h
for 10 days
Oral ciprofloxacin 750 mg
twice daily for 3 weeks
Outcome Number of doses
received prior to
clinical response
defined as reduction to
either < 100 mm or
< 50% of the initial
diameter and
resolution of fever;
diameter decrease;
pain VASb; patient
subjective improvement
Early clinical response Recovery: symptom rating
score of zero for erythema,
oedema and pain and
normal temperature.
Failure: no clinical
improvement in symptom
ratings
Long-term satisfactory
response: immediate
satisfactory response and
no rehospitalization related
to LLC within 12 months
ESTABLISH 1: temperature
< 37.6 °C, cessation of
lesion spread, no
concomitant antibiotics
and no mortality
ESTABLISH 2: ≥ 20%
reduction in lesion area,
no concomitant antibiotics,
no mortality
Clinical response at post-
therapy evaluation
ESTABLISH 1: as per early
response, no pain, mild or
no tenderness
ESTABLISH 2: as per early
clinical response
Timeframe for
follow-up
When clinical resolution
criteria met; diameter
decrease, VAS change
and patient subjective
improvement at Days 1
and 2
Early clinical response 48–
72 h; post-therapy
evaluation 7–14 days after
end of treatment
10 days 1 year
C, control; I, intervention; IM, intramuscular; IV, intravenous; LLC, lower limb cellulitis; VAS, visual analogue scale. aAll patients, not
LLC specifically; bVAS is a validated pain scale from 0 to 100, with 0 representing no pain and 100 maximal pain.
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complicated by allergic reactions and Clostridium diffi-
cile.23 With the increase in rates of resistance and
adverse events, it is important to identify new
antibiotics. Fear of MRSA and poor outcomes may
have driven overtreatment in the cases reported.24 A
previous review revealed 14% of cellulitis admissions
were overtreated.25
The main limitation of this review was the number
and quality of included studies. Although an abun-
dance of cellulitis literature existed, few focused on the
lower limb. As this is the first systematic review
focused on the antibiotic treatment of LLC, the less
stringent eligibility criteria provided a comprehensive
scope of the current literature.
This review identified a profound gap in the litera-
ture regarding high-quality studies to identify best
treatment of LLC. Future studies could explore
whether we can effectively treat mild LLC with less
intensive antibiotic regimens. Such regimens would
save health services money, reduce treatment compli-
cations and contribute to guidelines based on patient
characteristics.
Table 3 Summary of findings from outcome measures of clinical response in Leman and Mukherjee.13
Outcome
Flucloxacillin + benzylpenicillin Flucloxacillin alone
Mean difference (95% CI) Pan Mean (95% CI) n Mean (95% CI)
Doses to achieve clinical
response
38 8.47 (7.09 to 9.86) 38 8.71 (6.90 to 10.5) 0.24 (2.48 to 2.01) 0.83
Temperature drop, °C
(Day 1 minus Day 0)
35 0.36 (0.24 to 0.95) 32 0.42 (0.06 to 0.80) 0.07 (0.76 to 0.62) 0.84
Decrease in diameter, mm
Day 1 minus Day 0 26 36 (20 to 92) 22 69 (33 to 105) 34 (99 to 31) 0.30
Day 2 minus Day 0 13 95 (35 to 135) 12 46 (6 to 99) 48 (27 to 124) 0.20
VASb
Day 1 minus Day 0 24 2.6 (1.6 to 3.6) 23 2.5 (1.6 to 3.6) 0.10 (1.26 to 1.42) 0.91
Day 2 minus Day 0 16 3.0 (1.4 to 4.7) 16 2.9 (1.6 to 4.2) 0.15 (1.86 to 2.16) 0.88
aTwo-sample t-test; bVisual Analogue Scale (VAS)is a validated pain scale from 0 to 100, with 0 representing no pain and 100 maximal pain.
Table 4 Patient assessment of clinical response in Leman and
Mukherjee.13
Patient
subjective
assessment, n
(proportion)
Flucloxacillin +
benzylpenicillin
Flucloxacillin
alone RR (95% CI)a
Day 1
Improving 25 (0.74) 21 (0.68) 1.09 (0.79–1.49)
No change 9 (0.26) 8 (0.26)
Worse 0 (0) 2 (0.06)
Day 2
Improving 18 (0.82) 16 (0.84) 0.97 (0.74–1.28)
No change 1 (0.05) 0 (0)
Worse 3 (0.14) 3 (0.16)
RR, relative risk; a‘No change’ and ‘worse’ scores were combined
to calculate RR.
= low risk of bias
= high risk of bias
= unclear risk of bias
Study Bias from the 
randomization 
process
Bias due to 
deviations 
from the 
intended 
intervention
Bias due to 
missing 
outcome 
data
Bias in 
measurement 
of the 
outcome
Bias in 
selection of 
the reported 
result
Joseph 201714
Leman 200513
Peterson
198916
–
Zeglaoui
200415
–
Figure 2 Cochrane risk of bias assessment to illustrate the risk of bias for each domain in individual studies.
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Conclusion
The evidence for the clinical response to antibiotics for
LLC is limited; however, there is low-quality evidence to
support the possible use of shorter courses of lower doses
of oral antibiotics in some patients. Further trials compar-
ing lower-intensity antibiotic regimens are warranted.
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Learning points
• Cellulitis is a common condition that can have
a negative impact on patients; however, the clini-
cal response of different antibiotic treatment regi-
mens remains unclear.
• There is variation in the treatment of LLC, with
many patients failing to respond to first-line antibi-
otics, and an increase in antibiotic resistance.
• There is weak evidence that LLC may be over-
treated in some patients, for whom shorter courses
of lower-dose, oral antibiotics may be suitable.
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CPD questions
Learning objective
To demonstrate up-to-date knowledge in the manage-
ment of lower limb cellulitis.
Question 1
Which of the following is the most common location
of cellulitis?
(a) Face.
(b) Umbilicus.
(c) Genitals.
(d) Upper limb.
(e) Lower limb.
Question 2
Which of the following is an antibiotic used to treat
lower limb cellulitis, but may increase the risk of
methicillin-resistant Staphylococcus aureus?
(a) Vancomycin.
(b) Linezolid.
(c) Flucloxacillin.
(d) Clindamycin.
(e) Trimethoprim.
Question 3
Which of the following adverse effects is more com-
mon with antibiotics administered through the intra-
venous rather than intramuscular route?
(a) Venitis.
(b) Cutaneous skin necrosis.
(c) Nausea and vomiting.
(d) Anaphylaxis.
(e) Headache.
Question 4
Which of the following antibiotics are considered first
line in the UK for the treatment of cellulitis?
(a) Ciprofloxacin.
(b) Gentamicin.
(c) Fusidic acid.
(d) Chloramphenicol.
(e) Flucloxacillin.
Question 5
Which of the following statements regarding the treat-
ment of lower limb cellulitis is based on evidence in
the international literature?
(a) Intravenous benzylpenicillin results in a shorter
time to recovery compared with intramuscular
bipenicillin.
(b) The addition of intravenous benzylpenicillin to
intravenous flucloxacillin results in a more rapid
clinical response.
(c) Ciprofloxacin has no clinical response against
lower limb cellulitis.
(d) There appears to be no difference in the clinical
response to intravenous vs. oral antibiotics in the
treatment of cellulitis for some patients.
(e) Tedizolid has no clinical response against lower
limb cellulitis.
Instructions for answering questions
This learning activity is freely available online at
http://www.wileyhealthlearning.com/ced
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Users are encouraged to
• Read the article in print or online, paying particular
attention to the learning points and any author
conflict of interest disclosures.
• Reflect on the article.
• Register or login online at http://www.wileyhealth
learning.com/ced and answer the CPD questions.
• Complete the required evaluation component of the
activity.
Once the test is passed, you will receive a certificate
and the learning activity can be added to your RCP
CPD diary as a self-certified entry.
This activity will be available for CPD credit for
2 years following its publication date. At that time, it
will be reviewed and potentially updated and extended
for an additional period.
Supporting Information
Additional Supporting Information may be found in
the online version of this article:
Table S1. Eligibility citeria.
Table S2. Detailed search strategy.
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